Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
OP027

The rising incidence of early-onset paediatric inflammatory bowel disease (Paris A1a) in Scotland since 1981: a national, population-based, cohort study

Authors:

P. Henderson*1, F.L. Cameron1, F. Jagger2, R. Hansen3, H. Drummond4, E. Reynish5, S. Loganathan2, R.K. Russell3, J. Satsangi4, D.C. Wilson1

1University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom, 2Royal Aberdeen Children's Hospital, Department of Paediatric Gastroenterology, Aberdeen, United Kingdom, 3Royal Hospital for Sick Children, Paediatric Gastroenterology, Glasgow, United Kingdom, 4University of Edinburgh, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom, 5University of Stirling, School of Applied Social Science, Stirling, United Kingdom

OP028

Oral delivery of a new class of non-antibody protein scaffold Nanofitins targeting TNF-alpha shows a strong preventive and curative anti-inflammatory effect in models of inflammatory bowel diseases.

Authors:

M. Cinier*1, M. Zeisser Labouèbe2, C. Rousseaux3, J.V. Rodriguez4, A. Cunha4, N. Truong Tan3, R. Gurny2, L. Scapozza2, O. Kitten1

1Affilogic, Affilogic, Nantes, France, 2University of Geneva, School of Pharmaceutical Sciences, Geneva, Switzerland, 3Intestinal Biotech Development, Intestinal Biotech Development, Lille, France, 4Instituto de Biologia Experimental Tecnológica, iBET, Oeiras, Portugal

OP03. Induction of autophagy upon DC‑T cell contact is mediated by LKB1–AMPK–mTOR signalling
OP04. Mortality and cancer in paediatric inflammatory bowel disease: A population-based study
OP05. Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease
OP06. Endocytoscopy allows accurate in vivo differentiation of mucosal inflammatory cells in IBD – a pilot study
OP07. Use of fecal calprotectin as marker of disease activity in patients under maintenance treatment with infliximab for ulcerative colitis [on behalf of BIRD14]
OP08. SPARC modifies colonic tissue healing and inflammation by regulating collagen and MMP expression
OP09. Anti TNF‑α therapy is a major cost driver in inflammatory bowel disease: Results from the COIN study
OP10. Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis
OP11. Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial
OP12. Multiple functional variants at the 3p21 locus contribute to ulcerative colitis: Results from a European consortium
OP13. TLR4 signaling activates the Wnt pathway in a mouse model of colitis-associated neoplasia
OP14. Adenomas in patients with inflammatory bowel disease: Increased risk of advanced neoplasia
OP15. Immunosuppressive co-treatment with adalimumab (ADA) may be more effective than ADA monotherapy for maintaining remission in Crohn's disease (CD)
OP16. Adding ciprofloxacin to adalimumab results in a higher fistula closure rate in perianal fistulizing Crohn's disease [on behalf of ICC (Initative on Crohn's and Colitis)]
OP17. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. Study of prevalence and predictive factors. ENEIDA project
OP18. Long-term outcome after first intestinal resection in paediatric-onset Crohn's disease: A population-based study
OP19. Genetic and functional evidence for a role for CYLD in Crohn's disease: Results from a European consortium
OP20. TNF and MDP induce epithelial-to-mesenchymal transition in human intestinal cells: Implications for the pathogenesis of Crohn's disease-associated fistulae and the use of anti‑TNF antibodies